I am a PharmD that works in industry (not this company) so I like to invest in the sector as I know it personally better than other sectors.
What really got me about APRI is their product Vitaros. It is a topical ED cream that is approved in many European countries and sold via partnership. As well this product uses a proprietary inactive ingredient that increases permeability of the product to increase absorption making a topical route possible. Their direct competitors for this product are Caverject ( a injection device into the penis) or Muse (a urethral suppository you have to insert an inch or so in). Both products as a pharmacist make me cringe and I can see it being a barrier that this over comes.
Also in their pipeline is the first product and possibly only treatment for Raynaud's phenomenon. It's basically the same thing as Vitaros where the drug permeability product allows the active ingredient to be absorbed through the skin of the hands and feet to increase blood flow.
The problem is currently they are low on cash but have massively expanded Vitaros markets through partnership with Takeda, Sandoz, Ferring and Amgen. The product should be launched in the US and Latin America soon and they will be getting royalties on it.
I can see them starting to really pull in a steady stream of income by the middle of 2016 that will grow into 2017 on this product alone then add in if they get approval on their pipeline products and they look strong if they can maintain their Financials. They look well to be in a position to bring one of the first novel SERMs to market for low testosterone in males. Won't likely be the first but the first looks like it won't be novel rather an isomer of a current generic drug.
So anyone else looking at them? Have other thoughts or concerns as they appear rather undervalued to me so I must be missing something.
Submitted December 03, 2015 at 08:45AM by germican http://ift.tt/1lbwmXT
No comments:
Post a Comment